Cardiac Allograft Vasculopathy
Conditions
Keywords
identify early non invasive markers that index the endothelial lesion/ regeneration potential in association with CAV in heart transplanted recipients (HTR)
Brief summary
Heart transplantation is the best option for patients with end-stage heart failure. Cardiac allograft vasculopathy (CAV) is the leading cause of death following cardiac transplantation and is not managed by current therapies. Its pathogenesis traduces in an accelerated form of coronary artery disease (CAD) with similarities to atherosclerosis but also particular features of endothelial dysfunction associated to the alloimmune conflict and humoral responses toward the graft. Intravascular ultrasound (IVUS) is the validated invasive method for late CAV diagnosis, but occurs lesions are established. Identification of reliable non-invasive early endothelial injury biomarkers that reflect mechanisms of cardiac damage thus remain a major challenge to optimize therapeutic management of post transplant morbidity. Endothelial dysfunction is a central feature of both CAV and CAD and results from a desquilibrium in the balance of endothelial lesion and repair that is partly controlled by recipient immune system. Through their expression of receptors sensing antibodies (FcR CD16) and endothelial stress-induced signals (CX3CR1 fractalkine receptor and NKG2D MICA receptors), Natural Killer (NK) cells represent effector cells with unique potential to generate both humoral and innate immune injury of graft endothelium.
Interventions
BIOLOGICALblood samples
Sponsors
Assistance Publique Hopitaux De Marseille
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subject \> 18 years at the time of the inclusion, * Subject having benefited from a heart transplant more than 11 months ago in the service of cardiac surgery concerned whatever is the treatment to immunosuppresseur current * Subject benefiting from a coronarography within the framework of their surveillance comment-Clerk's Office beyond 12 months * Subject having given their consent * Affiliated to the Social Security \* HTC with Cardiac allograft vasculopathy: * Subject with coronaropathies diagnosed by the coronarography \* TC without Cardiac allograft vasculopathy: * Subject without coronaropathies diagnosed by the coronarography \* untransplanted * Untreated Subject by immunosuppresseurs * Subject without antécédaent of transfusion * Subject without history of transplantations * Subject with coronaropathies diagnosed by a coronarography
Exclusion criteria
* Presenting a contraindication to the coronarography * Subject refusing to practise the examination of coronarography * Subject reaches(affects) of a cancer other one than cutaneous * Subject achieves of hepatic Incapacity (ALAT and\\or ASAT \> 3N)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Analysis of endothelial lesion-repair biomarkers | 24 MONTHS | through phenotypic and quantitative analysis of circulating endothelial progenitors subsets and (repair potential) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Analysis of anti endothelial NK innate immune responses parameters | 24 MONTTHS | * Anti endothelial, anti HLA anti MIC antibody detection in recipient' serum by luminex and flow cytometry * Evaluation of soluble Fractalkine and MIC levels in serum through ELISA * Analysis of CX3CR1 and CD16 polymorphism and phenotypic NK cell surface expression * Assay of serum induced and natural NK cell cytotoxicity against coronary and endothelial cell targets |
Countries
France
Outcome results
None listed